Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic review of literature;Evaluación de la vacuna pandémica antigripal A/H1N1 adyuvada MF59. Revisión sistemática de la literatura

Anales de Pediatria

Volumn 79, Issue 4, 2013, Pages 208-217

  Ruiz Aragon J ^a   Grande Tejada, A M ^b   Marquez Pelaez S ^c   Molina Linde, J M ^c   Yang, R ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

^c UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^d Centro de Salud Mairena Del Aljarafe   (Spain)

Author keywords

Efficacy; Influenza A virus H1N1 subtype; Safety; Systematic review

Indexed keywords

ADJUVANT; INFLUENZA VACCINE; MIFAMURTIDE;

ANTIBODY TITER; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); PANDEMIC INFLUENZA; REVIEW; SEROCONVERSION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EFFICACY; EFICACIA; INFLUENZA A VIRUS H1N1 SUBTYPE; REVISIÓN SISTEMÁTICA; SAFETY; SEGURIDAD; SYSTEMATIC REVIEW; VACUNA PANDÉMICA A/H1N1;

ADJUVANTS, IMMUNOLOGIC; CHILD; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; POLYSORBATES; SQUALENE;

EID: 84884675617     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2013.01.022     Document Type: Article

References (25)

1. J.C. Buñuel Alvarez, and J. González de Dios Grupo de Trabajo de Pediatría Basada en la Evidencia (GT-PBE). Evidencias de la pandemia por virus influenza A (H1N1) An Pediatr (Barc) 71 2009 379 382
2. N.B. Halasa Update on the 2009 pandemic influenza A H1N1 in children Curr Opin Pediatr 22 2010 83 87
3. G. Della Cioppa, T. Vesikari, E. Sokal, K. Lindert, and U. Nicolay Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study Vaccine 29 2011 8696 8704
4. J. Marès, C. Rodrigo, D. Moreno-Pérez, M.J. Cilleruelo, F. Barrio, and J.C. Buñuel Recomendaciones sobre el tratamiento de la gripe en pediatría (2009-2010) An Pediatr (Barc) 72 2010 144.e1 144.e12
5. M. Jordan, M. Connock, E. Albon, A. Fry-Smith, B. Olowokure, and J. Hawker Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence Vaccine 24 2006 1047 1062
6. T. Vesikari, M. Knuf, P. Wutzler, A. Karvonen, D. Kieninger-Baum, and H.J. Schmitt Oil-in-water emulsion adjuvant with influenza vaccine in young children N Engl J Med 365 2011 1406 1416
7. T. Jefferson, A. Rivetti, C. Di Pietrantonj, V. Demicheli, and E. Ferroni Vaccines for preventing influenza in healthy children Cochrane Database Syst Rev 8 2012 CD004879
8. T. Vesikari, M. Pellegrini, A. Karvonen, N. Groth, A. Borkowski, and D.T. O'Hagan Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant Pediatr Infect Dis J 28 2009 563 571
9. S. Esposito, L. Pugni, C. Daleno, A. Ronchi, A. Valzano, and D. Serra Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months Pediatrics 127 2011 e1161 e1168
10. S.L. Block, G.M. Ruiz-Palacios, M.L. Guerrero, J. Beygo, V. Sales, and S.J. Holmes Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children Pediatr Infect Dis J 31 2012 e92 e98
11. A. Arguedas, C. Soley, A. Abdelnour, V. Sales, K. Lindert, and G. Della Cioppa Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1 v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age Hum Vaccin 7 2011 58 66
12. U.S. Food and Drug Administration [Internet]. Centre for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines [consultado 15 Jun 2012]. Disponible en: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm
13. Programa de lectura crítica CASPe [Internet]. Entendiendo la evidencia sobre la eficacia clínica. 11 preguntas para entender un ensayo clínico [consultado 12 Jun 2012]. Disponible en: http://www.redcaspe. org/herramientas/lectura/11ensayo.pdf
14. S. Candela, S. Pergolizzi, P. Ragni, S. Cavuto, L. Nobilio, and S. Di Mario An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria(®) in a province of Emilia-Romagna region, Italy - Part one Vaccine 31 2013 1431 1437
15. C.E. Oh, J. Lee, J.H. Kang, Y.J. Hong, Y.K. Kim, and H.J. Cheong Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial Vaccine 28 2010 5857 5863
16. X.F. Liang, H.Q. Wang, J.Z. Wang, H.H. Fang, J. Wu, and F.C. Zhu Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 375 2010 56 66
17. F.C. Zhu, H. Wang, H.H. Fang, J.G. Yang, X.J. Lin, and X.F. Liang A novel influenza A (H1N1) vaccine in various age groups N Engl J Med 361 2009 2414 2423
18. G.V. Zuccotti, E. Pariani, A. Scaramuzza, L. Santoro, E. Giani, and M. Macedoni Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus Diabet Med 28 2011 1530 1536
19. S. Esposito, E. Meregalli, C. Daleno, L. Ghio, C. Tagliabue, and A. Valzano An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients Nephrol Dial Transplant 26 2011 2018 2024
20. H. Fukase, H. Furuie, Y. Yasuda, R. Komatsu, K. Matsushita, and T. Minami Assessment of the immunogenicity and safety of varying doses of an MF59(®)-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects Vaccine 30 2012 5030 5037
21. C. Nassim, S. Christensen, D. Henry, S. Holmes, M. Hohenboken, and N. Kanesa-Thasan Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age Pediatr Infect Dis J 31 2012 e59 e65
22. Y. Yasuda, R. Komatsu, K. Matsushita, T. Minami, Y. Suehiro, and H. Sawata Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1 v vaccine in Japanese children Adv Ther 27 2010 444 457
23. H.J. Cheong, J.Y. Song, J.Y. Heo, J.Y. Noh, W.S. Choi, and D.W. Park Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus non-adjuvanted vaccine Clin Vaccine Immunol 18 2011 1358 1364
24. T.F. Tsai MF59 Adjunvanted seasonal and pandemic influenza vaccines Yakugazu Zasshi 131 2011 1733 1741
25. L. Manzoli, J.P. Ioannidis, M.E. Flacco, C. De Vito, and P. Villari Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: A critical review and re-analysis of 15 meta-analyses Hum Vaccin Immunother 8 2012 851 862